Kinox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kinox

Property Description
Active ingredient Ciprofloxacin
Form Tablet, Solution (Intravenous, Ophthalmic, Otic)
Pharmacological class Fluoroquinolone Antibiotic
General purpose Antiinfective (for bacterial pathogens)
Origin Synthetic

What is Kinox and What Type of Drug is it?

Kinox is a prescription-only medicine whose active ingredient is Ciprofloxacin, a compound used exclusively to combat infections caused by susceptible bacteria. Ciprofloxacin is a potent member of the fluoroquinolone pharmacological class, a category recognized in clinical guidelines for its efficacy in clearing severe infections. This classification establishes Kinox as an antibiotic and synthetic broad-spectrum antimicrobial agent, confining its use strictly to addressing bacterial pathogens.

Composition, Origin, and General Purpose

The medication is composed solely of Ciprofloxacin as the active ingredient and is entirely synthetic in origin, commonly formulated as the monohydrochloride monohydrate salt. Ciprofloxacin is prepared in several essential dosage form(s), including the film-coated tablet for oral intake, or as a sterile intravenous solution for systematic delivery in controlled settings. The general function of Ciprofloxacin is to serve as a robust antiinfective agent to eradicate the source of established bacterial infections. The general purpose of the drug is, therefore, to provide a tool for the control and elimination of these infectious organisms throughout the body.

The Bactericidal Principle: How Ciprofloxacin Works (High-Level)

The functional identity of Ciprofloxacin rests on its powerful bactericidal effect, which means the drug works by actively killing the invading bacteria. This physiological action is accomplished by interfering with vital bacterial enzymes, specifically DNA gyrase and topoisomerase IV, thereby preventing the pathogens from replicating their genetic material and ensuring they cannot reproduce. This targeted disruption is clinically recognized for its ability to provide a decisive elimination of bacterial pathogens, enabling the clearance of infection.

What side effects are possible with Kinox?

Kinox's safety profile, as documented in official government regulatory information, classifies adverse reactions by frequency and affected body systems. Common reactions officially listed include nausea, diarrhea, vomiting, headache, and dizziness. These are noted alongside a spectrum of uncommon and rare effects affecting systems such as the musculoskeletal and nervous systems, including joint pain (arthralgia) and confusion.

The regulatory documents highlight several serious and potentially irreversible risks. These include the documented possibility of tendinitis and tendon rupture, as well as damage to the nerves outside the brain and spinal cord, known as peripheral neuropathy. Both effects may be long-lasting or permanent and can begin hours to months after treatment. Other serious documented risks involve central nervous system effects (like seizures and psychotic reactions), disturbances in blood sugar (hypoglycaemia), and cardiovascular concerns like QT prolongation and the documented risk of aortic aneurysm and dissection.

Safety considerations for specific populations are explicitly stated. Older adults and individuals with renal impairment are recognized as having an altered risk profile, with dose adjustments sometimes required for the latter. The medicine is officially indicated to be avoided in patients with a history of Myasthenia Gravis due to the risk of exacerbating muscle weakness. For certain less severe infections, its use is reserved only for situations where no alternative treatment options are available, a restriction formally noted due to the serious adverse reactions.

Overdose and Emergency Response

Kinox Overdose and When to Seek Help

An overdose of Kinox (Ciprofloxacin) may present with specific manifestations documented in regulatory prescribing information. Primary signs often involve the Central Nervous System (CNS), including dizziness, tremor, headache, and acute states of confusion. In instances of massive overdose, severe CNS excitation resulting in convulsions or seizures may occur.

A significant physiological manifestation of overdose is the precipitation of drug substance, known as crystalluria, which can lead to severe outcomes such as acute renal failure. The official labeling notes that patients with impaired renal function are at an increased risk for complications arising from crystalluria.

Due to these serious risks, the explicit regulatory instruction is to seek immediate medical attention for any suspected overdose. Management procedures described in official documents are entirely symptomatic and supportive, as no specific antidote is known. Recommended supportive measures include methods for gastric emptying, administration of activated charcoal, and crucially, maintaining adequate hydration to mitigate the risk of crystalluria. Close hospital observation and monitoring of renal function are required.

Therapeutic Uses of Kinox

What Kinox Treats: Main Uses and Benefits

Kinox (Ciprofloxacin) is commonly used to help with a range of acute and complicated clinical conditions. The primary benefit of its use is to provide supportive relief and help ease the overall symptom load associated with the infection. The medication is considered relevant across therapeutic domains involving heightened symptomatic responses.

The medication is commonly used to help with acute or recurrent infections affecting the genitourinary tract (such as complicated UTIs and pyelonephritis), deep-seated bone and joint infections, chronic bacterial prostatitis, specific types of infectious diarrhea, and respiratory tract conditions like acute exacerbations of chronic bronchitis. Kinox may also be part of symptomatic management in high-risk contexts, including post-exposure support for inhalational anthrax.

“The goal of treatment is to address symptom clusters that may become intense or disruptive, contributing to improved comfort during symptomatic periods.”

This therapeutic focus helps manage symptoms related to systemic imbalance (like high fever and chills) and symptoms linked to organ-specific functional stress (such as painful urination or severe diarrhea). Its use supports the patient by assisting with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Support for Acute Symptom Clusters Kinox is applied in clinical settings that involve acute or unstable symptom patterns, helping to manage sudden flare-ups associated with high systemic burden and significant functional strain.

Eligibility and Restrictions for Use

Kinox (Ciprofloxacin) eligibility is defined by official regulatory documents through absolute prohibitions and specific restrictions based on patient characteristics.

Eligibility Scope

Scope Regulatory Statement
Populations for whom use is allowed Adults (18 years and older) for approved infections. Pediatric patients (1–17 years) are eligible only for specific, severe infections like complicated urinary tract infections and post-exposure anthrax.
Populations for whom use is contraindicated Patients with a known hypersensitivity to ciprofloxacin or any other fluoroquinolone. Patients receiving concomitant administration of Tizanidine.

Age and Condition-Based Restrictions

Category Eligibility Rule
Age-Related Rule Use is not generally recommended for children and adolescents due to musculoskeletal risks. Older adults (over 60 years) require special caution due to increased risk of tendon disorders.
Condition-Specific Rule Use must be avoided in patients with a history of Myasthenia Gravis. Caution is required for patients with renal impairment, a history of seizures/epilepsy, or known QT prolongation risk factors.

Reproductive Status

Use during pregnancy is not generally recommended unless the potential benefit outweighs the risk. Lactation/breastfeeding is not recommended as the drug is excreted into breast milk.

What should I know about interactions with other medicines?

Kinox Interactions with other medicines and products

Kinox (Ciprofloxacin) has documented interaction patterns that necessitate specific restrictions and administration timing rules based on official regulatory labeling. Co-administration with Tizanidine is strictly contraindicated by health authorities due to a pharmacokinetic interaction that significantly raises Tizanidine's plasma levels, increasing the risk of adverse effects. A high-level pharmacodynamic risk is associated with combining Kinox with other medicinal products known to prolong the QT interval (e.g., certain antiarrhythmics or antipsychotics), as regulatory documents note the potential for additive effects.

Kinox is classified as a moderate inhibitor of the CYP1A2 enzyme. This metabolic interaction decreases the clearance of certain co-administered drugs, including Theophylline and Caffeine, leading to elevated systemic exposure of these substances. Regulatory documents mandate specific monitoring procedures, such as for Theophylline and when Kinox co-occurs with Warfarin, as it may enhance the anticoagulant effect.

A mandatory timing separation is required for oral Kinox when administered with products containing multivalent cations (e.g., aluminum/magnesium antacids, iron, zinc supplements, or Sucralfate). These agents cause reduced Kinox absorption via chelation, and must be taken at least 2 hours before or 6 hours after Kinox. Similarly, taking oral Kinox only with dairy products or calcium-fortified juices should be avoided due to the potential for reduced bioavailability. Population-specific cautions note that elderly patients have an increased risk of specific interactions, such as QT interval prolongation, when combined with interacting agents.

Mechanism of Action

How Kinox Works

Kinox works exclusively by interfering with the essential processes required for bacterial maintenance: the maintenance and replication of its genetic material. Its action is strictly bactericidal, resulting in the active killing of susceptible bacteria.


Molecular Targets: Blockade of DNA Gyrase and Topoisomerase IV

Ciprofloxacin's primary sites of action are the essential bacterial enzymes DNA Gyrase and DNA Topoisomerase IV. The molecule functions as an inhibitor, binding to and stabilizing the cleavage complex that forms when these enzymes temporarily break the DNA strand. This mechanical blockade prevents the DNA from being properly resealed.


Mechanistic Cascade: Induction of Lethal DNA Damage

The failure to reseal the bacterial DNA initiates a rapid, cytotoxic sequence. The fixed, broken DNA strands lead to the accumulation of lethal DNA double-strand breaks (DSBs) as the bacterial cell attempts replication or repair. This overwhelming genetic damage forces the activation of bacterial cell death pathways, directly resulting in the cellular destruction of the microbial population and the cessation of the pathogen's viability.


Mechanism Constraints: Resistance through Target Modification and Efflux

The drug's mechanism is physiologically constrained by the pathogen's ability to evolve. Mechanisms include target-mediated constraint, where mutations in the bacterial gyrA and parC genes reduce the drug's affinity for its enzyme targets. Additionally, bacterial efflux pumps can actively transport the drug out of the cell, lowering its effective intracellular concentration and undermining the bactericidal cascade.

Dosage and Administration Information

Official Administration and Dosing Principles

Kinox (Ciprofloxacin) is supplied for systemic delivery via the oral route, including immediate-release tablets and oral suspension, and as a solution for intravenous (IV) infusion. The therapy often transitions from IV to the oral form in a planned process known as sequential therapy once the patient is clinically stable.

Administration follows a strict schedule, with the standard regimen for most systemic infections being twice daily (every 12 hours). Dosing is precisely mandated by strength, typically ranging from 250 mg to 750 mg per oral dose or 200 mg to 400 mg per IV dose. For severe or complicated infections, the IV administration may be increased to 400 mg three times daily.

Oral tablets may be taken with or without food; however, administration must be separated from dairy products (e.g., milk, yogurt) and supplements containing multivalent cations (e.g., antacids or iron supplements) to ensure proper intake. The intravenous solution is required to be administered as a slow infusion over a period of 30 to 60 minutes. Explicit dose adjustments are required for patients with impaired renal function (kidney issues), necessitating a reduction in the dose amount or an extension of the interval between administrations. The total duration of therapy ranges from short courses (e.g., three days for uncomplicated infections) to long-term use (e.g., 60 days for specific post-exposure regimens).

Recent Clinical Evidence

Kinox is a brand name for inhaled nitric oxide (iNO), a selective pulmonary vasodilator gas. Clinical evidence for iNO focuses primarily on its use in hospital settings to manage pulmonary hypertension associated with severe respiratory conditions.


Efficacy and Oxygenation

Clinical trials have primarily evaluated iNO in term and late pre-term neonates (born at ge 34 weeks' gestation) experiencing hypoxic respiratory failure with evidence of pulmonary hypertension. Findings from two major studies reported:

  • Significantly fewer neonates who received iNO required extracorporeal membrane oxygenation (ECMO) compared to control groups (e.g., 31% vs. 57% in one trial). ECMO is a life-support measure used when a patient's lungs and heart are unable to function on their own.
  • The combined incidence of death and/or receipt of ECMO was measured as lower in the iNO-treated group compared to the control group.

Evidence also supports the use of iNO in peri- and post-operative pulmonary hypertension episodes in patients of all ages undergoing heart surgery, where it is used in conjunction with ventilatory support to selectively reduce pulmonary arterial pressure.


Safety and Tolerability

Studies examining the safety profile of iNO have noted that it is generally administered under close monitoring in intensive care settings. A safety review found a possible link between nitric oxide use and the risk of pulmonary edema in individuals with pre-existing pulmonary veno-occlusive disease (PVOD). The principal metabolites, methemoglobin and nitrates, are eliminated primarily through the urine.

Key Studies & References Pulmonary Hypertension in Neonates and Children: Diagnosis and Management.

Frequently Asked Questions (FAQ)

Common questions about Kinox (FAQ)


Q: How quickly can someone expect Kinox to start working?

According to official product information, after taking an oral dose, the medicine's concentration in the blood typically reaches its highest level within 1 to 2 hours. This metric provides insight into the speed of drug absorption and availability within the body.


Q: What is the total duration of effect for a dose of Kinox?

Regulatory information indicates that the time it takes for half of the medicine to be eliminated from the body, known as the half-life, is approximately 4 hours for individuals with healthy kidney function. The half-life helps healthcare providers determine appropriate dosing schedules to maintain effective levels.


Q: Does Kinox have a generic version available yet?

The active ingredient in Kinox is Ciprofloxacin. Official information indicates that Ciprofloxacin is a well-established compound available in a variety of generic products.


Q: Are there any long-term safety concerns associated with Kinox use?

Official warnings note that certain serious reactions affecting the musculoskeletal system (like tendons) and the nervous system (like peripheral neuropathy) have been reported to be long-lasting or potentially irreversible. These serious effects have been reported to occur during treatment or months after it has been stopped.


Q: Is there a list of major drug classes that interact with Kinox?

Official documents describe interactions with specific drugs (such as Tizanidine and Theophylline) and also mention drug classes that require careful use. These include agents known to prolong the QT interval (a heart rhythm measurement) and certain antidiabetic medicines.


Q: Why do doctors check liver function before prescribing Kinox?

Hepatotoxicity, or liver damage, is an officially reported risk. Regulatory guidance advises immediate discontinuation if signs of hepatitis (liver inflammation) occur. Assessment of hepatic function may be considered by healthcare providers during prolonged therapy.


Q: What is the risk classification of Kinox?

Kinox (Ciprofloxacin) was previously assigned the U.S. FDA Pregnancy Category C, meaning animal studies showed some risk to the fetus. Official guidance cautions that potential benefits in pregnant women must be considered to outweigh any potential risks.


Q: Does Kinox require a special prescription or monitoring?

The drug is available by prescription only. Official guidance advises cautious use with specific monitoring (such as heart rhythm or blood sugar checks) when the patient has certain conditions or is using interacting medicines. The need for specific monitoring is determined based on the patient’s condition and co-administered medicines.


Q: Is Kinox known to affect sleep patterns?

Official safety information reports Central Nervous System (CNS) effects, including insomnia (trouble sleeping), agitation, and nightmares.


Q: Do any specific foods need to be avoided while using Kinox?

When taking the oral tablet form, official documents state it should not be taken solely with dairy products (like milk or yogurt) or calcium-fortified juices. These products can decrease the amount of medicine the body absorbs. Official guidance permits taking the medicine with a meal that contains these products, but advises against taking the dose only with these products.


Q: How does the body eliminate Kinox after it's taken?

Official pharmacological data indicates that the body primarily removes the unchanged medicine via the urine. Additionally, four less active substances (metabolites) are also excreted in the urine.


Q: Are the effects of Kinox permanent after stopping the medicine?

The drug’s therapeutic effect stops once the medicine is cleared from the body. However, official warnings note that serious adverse reactions, such as peripheral neuropathy and tendon rupture, have been reported to be long-lasting or potentially irreversible even after treatment has ended.


Q: Can Kinox be stopped suddenly, or does it need to be tapered?

The therapy duration is based on clinical necessity to eliminate the infection, and regulatory documents do not specify a mandatory tapering schedule. Official guidance states that therapy should generally be continued for at least two days after the signs and symptoms of infection have disappeared.


Q: What is the maximum allowed period of time a person can be on Kinox?

The total duration of treatment is fixed by the official label, varying significantly based on the type of infection being treated. Durations can range from a short course of a few days up to 60 days for specific post-exposure prophylaxis regimens.


Q: Is it true that Kinox is only for severe cases?

No, the medicine is approved for a range of infections. However, official warnings state that for certain less severe conditions, such as some types of bronchitis, the drug is reserved only for patients who have no other available treatment options due to the risk of serious side effects.


Q: What are the reported effects of Kinox on driving or operating machinery?

The official label advises that patients should avoid driving, operating machinery, or participating in hazardous activity until they know how Kinox affects them. This caution is related to the potential for central nervous system side effects that may impair concentration and physical reactions.


Q: Does Kinox have a risk of causing allergic reactions?

Serious hypersensitivity reactions (allergic reactions), including a severe reaction called anaphylaxis, have been reported. These reactions may occur after the very first dose or subsequent doses of the medicine.


Q: Are there any known interactions between Kinox and vaccines?

Official information states that Ciprofloxacin can reduce the activity of the live Typhoid Vaccine. A healthcare provider can determine the appropriate timing between the antibiotic and the live vaccine.


Q: What should I do if I notice a change in the color of my urine while on Kinox?

Official guidance advises patients to notify their healthcare provider immediately if they experience symptoms that could indicate a serious reaction, such as dark urine. This symptom can be a sign of a serious liver problem, or hepatotoxicity, and requires prompt attention.


Q: Does Kinox interact with common over-the-counter pain relievers?

Regulatory documents do not specifically list common over-the-counter pain relievers (like ibuprofen or acetaminophen). However, official guidance advises caution for co-administration with other medicines that are known to prolong the QT interval, a heart rhythm measurement.


Q: Can Kinox be taken with basic supplements like vitamins or iron?

Kinox must not be taken at the same time as supplements containing multivalent cations, which include iron, calcium, zinc, and magnesium. These substances reduce the absorption of Kinox. Official guidance specifies that their intake must be separated by several hours to avoid this effect.


Q: How does the official guidance define the appropriate patient group for Kinox?

Official guidance determines the appropriate patient group primarily based on the specific bacterial infection being treated, such as lower respiratory tract or complicated urinary tract infections. It also includes limitations based on age, with adults generally eligible, and pediatric use reserved for only specific severe infections.


Q: Are there different forms (e.g., tablet, capsule) of Kinox available?

The approved dosage forms listed in the official product information include the film-coated tablet, an oral suspension, and a solution for intravenous injection. Capsules are not officially listed as an approved form.


Q: What kind of studies were performed to confirm the use of Kinox?

The approved uses for Kinox are confirmed by clinical studies. These studies demonstrated the drug's efficacy and safety in treating susceptible bacterial infections, including those affecting the urinary tract, lower respiratory tract, and other designated body systems.


Q: Why is the drug required to be kept in its original packaging?

The tablets must be stored at a controlled room temperature, protected from intense light, and maintained in a tightly closed container. The original packaging is designed to meet these specific storage conditions and help ensure the stability of the medicine.


Q: Does Kinox need to be taken at a specific time of day?

The required interval between doses is typically 12 hours. While the drug can be taken with or without food, maintaining this specific interval is necessary for consistent drug levels.


Q: What happens if I take Kinox at the wrong time of day?

Regulatory documents emphasize maintaining a consistent dosing interval to ensure the medicine’s concentration remains effective against the pathogen. Mistiming a dose may require consulting the official guidance.


Q: Is Kinox used for any non-primary indications (excluding off-label discussion)?

The drug is officially indicated for a comprehensive list of infections. This includes specific prophylactic uses, which are preventive, such as post-exposure prophylaxis for inhalational anthrax and plague.

How should Kinox be stored and disposed of?

Storage and Disposal Requirements for Kinox (Ciprofloxacin)

Kinox must be stored and disposed of according to official regulatory specifications to maintain its stability and ensure safety.


Storage Conditions

Tablets must be kept at controlled room temperature, generally 20 C to 25 C (68 F to 77 F), and protected from intense UV light. Keep all forms in a tightly closed container.

Prohibited Environments: All forms must be protected from freezing; the medicine is explicitly classified as Do not freeze.

Child Safety: Kinox must be kept out of the sight and reach of children.

Stability and Disposal

Oral Suspension: The reconstituted liquid is stable for a maximum of 14 days when stored at or below 25 C. Any unused portion must be thrown away after this period. Expired or no longer needed Kinox must be safely thrown away according to FDA guidelines or local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kinox found in:

A-Z Index: